Hans‐René Bjørsvik

Hans‐René Bjørsvik

Auto-generated profile, based on publicly available information

Hans‐René Bjørsvik

Department of Chemistry, University of Bergen, Allégaten 41, N-5007 Bergen, Norway

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2016 in European Journal of Organic Chemistry
Verified
Journal Article
Closed access
PDF file
HBHans‐René Bjørsvik
Hans‐René Bjørsvik
VEVijayaragavan Elumalai
Vijayaragavan Elumalai

12 October 2011 in ChemSusChem
Verified
Journal Article
Closed access
PDF file
RSRaffaele Spaccini
Raffaele Spaccini
LLLucia Liguori
Lucia Liguori
Carlo PuntaCarlo Punta
Carlo Punta
HBHans‐René Bjørsvik
Hans‐René Bjørsvik

14 October 2005 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
RGRaquel Rodríguez González
Raquel Rodríguez González
LLLucia Liguori
Lucia Liguori
ACAlberto Martinez Carrillo
Alberto Martinez Carrillo
HBHans-René Bjørsvik
Hans-René Bjørsvik

12 December 2011 in ChemSusChem
Verified
Journal Article
Closed access
PDF file
ATAnna Tsoukala
Anna Tsoukala
LPLudmila Peeva
Ludmila Peeva
ALAndrew G. Livingston
Andrew G. Livingston
HBHans‐René Bjørsvik
Hans‐René Bjørsvik

1 October 2004 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
HBHans-René Bjørsvik
Hans-René Bjørsvik
RGRaquel Rodríguez González
Raquel Rodríguez González
LLLucia Liguori
Lucia Liguori

6 August 2015 in ChemMedChem
Verified
Journal Article
Open access
PDF file
ASAlexander H. Sandtorv
Alexander H. Sandtorv
CLCalum Leitch
Calum Leitch
SBSiv Lise Bedringaas
Siv Lise Bedringaas
BGBjorn T Gjertsen
Bjorn T Gjertsen
HBHans‐René Bjørsvik
Hans‐René Bjørsvik
Computational chemistry has shown that backbone‐alkylated imidazoles ought to be efficient ligands for transition metal catalysts with improved carbene‐to‐metal donation. In this work, such alkylated imidazoles were synthesized and complexed with silver(I) by means of an eight/nine‐step synthetic pathway we devised to access a new class of biologically active silver complexes. The synthesis involves selective iodination of the imidazole backbone, followed by Sonogashira coupling to replace the backbone iodine. The installed alkyne moiety is then subjected to reductive hydrogenation with Pearlman’s catalyst. The imidazole N1 atom is arylated by the palladium‐catalyzed Buchwald N‐arylation method. The imidazole N3 position was then methylated with methyl iodine, whereupon the synthesis was terminated by complexation of the imidazolium salt with silver(I) oxide. The synthetic pathway provided an overall yield of ≈20 %. The resulting complexes were tested in vitro against HL60 and MOLM‐13 leukemic cells, two human‐derived cell lines that model acute myeloid leukemia. The most active compounds exhibiting low IC50 values of 14 and 27 μM, against HL60 and MOLM‐13 cells, respectively. The imidazole side chain was found to be essential for high cytotoxicity, as the imidazole complex bearing a C7 side chain at the 4‐position was four‐ to sixfold more potent than the corresponding imidazole elaborated with a methyl group.